Cinnamon, a widely used culinary spice, has generated interest as a potential complementary approach for managing type 2 diabetes. Laboratory studies suggest that bioactive compounds in cinnamon—particularly polyphenols and cinnamaldehyde—may influence glucose metabolism and insulin sensitivity. However, cinnamon is not licensed by the MHRA as a treatment for diabetes and is not recommended by NICE for glycaemic control. Clinical trial evidence remains mixed and inconclusive. Patients with type 2 diabetes should view cinnamon as a food ingredient rather than a medicine and discuss any supplementation with their healthcare team, particularly if taking prescribed diabetes medications.

What Is the Link Between Cinnamon and Type 2 Diabetes?

Cinnamon, a popular culinary spice derived from the bark of Cinnamomum trees, has attracted considerable interest as a potential complementary approach to managing type 2 diabetes. The proposed link centres on bioactive compounds found in cinnamon—particularly polyphenols and cinnamaldehyde—which laboratory studies suggest may influence glucose metabolism and insulin sensitivity.

Type 2 diabetes is characterised by insulin resistance and progressive beta-cell dysfunction, leading to elevated blood glucose levels. Conventional management includes lifestyle modification, oral hypoglycaemic agents such as metformin, and in some cases insulin therapy. Against this backdrop, some researchers have investigated whether cinnamon supplementation might offer additional glycaemic benefits when used alongside standard treatments.

It is important to emphasise that cinnamon is not licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) as a treatment for type 2 diabetes. Cinnamon products are regulated as foods or food supplements, not medicines. The National Institute for Health and Care Excellence (NICE) does not recommend cinnamon for glycaemic control. Whilst preliminary research has explored potential mechanisms, cinnamon remains an area of ongoing investigation rather than an evidence-based therapeutic intervention.

Two main species are used: Cinnamomum cassia (cassia or Chinese cinnamon) and Cinnamomum verum (Ceylon or true cinnamon). This distinction matters because cassia cinnamon contains significantly higher levels of coumarin, a compound that may pose safety concerns at high intakes.

Patients with type 2 diabetes should view cinnamon as a culinary ingredient rather than a medicine. Any consideration of cinnamon supplementation should be discussed with a healthcare professional, particularly for individuals taking prescribed diabetes medications, to avoid potential interactions or unrealistic expectations about glycaemic control.

How Cinnamon May Affect Blood Sugar Levels

The proposed mechanisms by which cinnamon might influence blood glucose are based primarily on preclinical laboratory and animal studies. These findings do not establish clinical efficacy in humans. Polyphenolic compounds in cinnamon, including proanthocyanidins, are thought to enhance insulin receptor signalling and improve cellular glucose uptake in experimental models. These compounds may mimic insulin activity or potentiate the effects of endogenous insulin, thereby theoretically reducing blood glucose concentrations.

Cinnamon extracts have also been studied in vitro for their potential to inhibit certain digestive enzymes, such as alpha-glucosidase, which breaks down carbohydrates into simple sugars. By slowing carbohydrate digestion, cinnamon might reduce post-prandial (after-meal) glucose spikes—a mechanism similar in principle to that of acarbose, a licensed medication for type 2 diabetes. However, this mechanistic similarity does not imply clinical equivalence, and the clinical significance of this effect in humans remains uncertain.

Additionally, some research suggests cinnamon may have antioxidant and anti-inflammatory properties that could theoretically benefit metabolic health. Chronic low-grade inflammation is recognised as a contributor to insulin resistance, and compounds that reduce inflammatory markers might indirectly support glycaemic control.

It is crucial to note that these mechanisms are largely theoretical when applied to human physiology. The concentrations of active compounds used in laboratory settings often far exceed what would be consumed through dietary cinnamon or even typical supplement doses. Furthermore, the bioavailability of these compounds—how much is actually absorbed and utilised by the body—varies considerably depending on the preparation (ground spice, aqueous or ethanolic extracts, or oils) and is not fully understood. Patients should not rely on cinnamon to lower blood sugar levels without medical supervision.

Evidence from Clinical Studies on Cinnamon for Diabetes

Clinical trials examining cinnamon supplementation in people with type 2 diabetes have produced mixed and inconsistent results. Some small-scale studies have reported modest reductions in fasting blood glucose or HbA1c (a measure of average blood glucose over 2–3 months), whilst others have found no significant benefit. A key challenge in interpreting this evidence is the considerable variation in study design, including differences in cinnamon species (Cinnamomum cassia versus Cinnamomum verum), dosage, duration, and participant characteristics.

Several systematic reviews and meta-analyses have attempted to synthesise the available evidence. Whilst some analyses suggest small reductions in fasting glucose (typically in the range of 0.5–1.0 mmol/L), the clinical significance of these findings is debatable, and the certainty of evidence is low due to high heterogeneity and methodological limitations. Effect sizes for HbA1c are inconsistent and very modest. Many studies have been criticised for small sample sizes, lack of blinding, and inadequate control for confounding variables such as diet and physical activity.

Importantly, no high-quality, large-scale randomised controlled trials have demonstrated that cinnamon supplementation provides clinically meaningful glycaemic benefits in people with type 2 diabetes. NICE does not recommend cinnamon for glycaemic control. The evidence base remains insufficient to support clinical recommendations.

Patients should be aware that individual responses to cinnamon may vary, and any perceived benefits could be due to placebo effects or concurrent lifestyle changes. There is also concern about the coumarin content in cassia cinnamon. The European Food Safety Authority (EFSA) has established a tolerable daily intake (TDI) for coumarin of 0.1 mg per kilogram of body weight per day. Cassia cinnamon typically contains approximately 2–5 mg of coumarin per gram (though this varies), meaning that just 1–2 teaspoons (approximately 2–4 grams) of cassia cinnamon daily could exceed the TDI for many adults and pose hepatotoxic (liver damage) risks with regular consumption. Ceylon cinnamon contains much lower levels of coumarin and may be a safer choice for regular use, though it does not alter the lack of evidence for glycaemic benefit.

Safe Use of Cinnamon Alongside Diabetes Medications

For individuals with type 2 diabetes taking prescribed medications, caution is essential when considering cinnamon supplementation. Whilst culinary use of cinnamon in normal food quantities is generally safe, concentrated supplements may interact with diabetes medications and increase the risk of hypoglycaemia (dangerously low blood sugar).

Key safety considerations include:

• Hypoglycaemia risk: The risk of hypoglycaemia varies by medication class. Insulin and insulin secretagogues (sulfonylureas such as gliclazide, or meglitinides such as repaglinide) carry the highest risk of hypoglycaemia. If cinnamon does have glucose-lowering effects, combining it with these medications could potentiate their effects, leading to blood glucose levels dropping too low. Metformin, SGLT2 inhibitors, and GLP-1 receptor agonists have a low risk of hypoglycaemia when used alone, but caution is still warranted if they are combined with insulin or secretagogues. Symptoms of hypoglycaemia include sweating, tremor, confusion, and in severe cases, loss of consciousness.

• Coumarin toxicity: Cassia cinnamon contains higher levels of coumarin than Ceylon cinnamon. The EFSA tolerable daily intake (TDI) for coumarin is 0.1 mg per kilogram of body weight per day. Cassia cinnamon typically contains around 2–5 mg of coumarin per gram, meaning that regular consumption of even modest amounts (1–2 teaspoons daily) can exceed safe limits for many adults. Chronic high-dose consumption may cause liver damage, particularly in individuals with pre-existing hepatic conditions or those taking other hepatotoxic medications. Lower limits apply to children due to their lower body weight.

• Lack of standardisation: Cinnamon supplements are not regulated as medicines in the UK. Product quality, purity, and active compound content can vary significantly between brands, making it difficult to predict effects or ensure safety.

• Pregnancy, breastfeeding, and children: High-dose cinnamon supplements should be avoided during pregnancy and breastfeeding due to limited safety data. They are also not recommended for children. Culinary amounts are generally considered safe.

• Liver disease: Individuals with liver disease or those taking hepatotoxic medications should seek clinical advice before using cinnamon supplements.

• Cinnamon essential oils: Do not take cinnamon essential oils orally, as they can cause irritation and toxicity.

Patients should always inform their GP or diabetes specialist nurse before starting any supplement, including cinnamon. Healthcare professionals can assess individual risk factors, review current medications, and advise on appropriate blood glucose monitoring. Self-medication without professional guidance is not recommended, as it may compromise diabetes control and overall safety.

If hypoglycaemic symptoms occur, patients should check their blood glucose immediately. If levels are below 4 mmol/L, treat promptly with fast-acting carbohydrate (e.g., glucose tablets, sugary drink). Call 999 if the person is unconscious, having seizures, or unable to swallow. Seek urgent medical advice for persistent severe hyperglycaemia (e.g., blood glucose persistently above 20 mmol/L), vomiting, or dehydration.

Report suspected side effects: If you experience any suspected adverse reactions from cinnamon supplements or any medicine, report them via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or by searching for 'Yellow Card' in the Google Play or Apple App Store.

NHS and NICE Guidance on Complementary Approaches to Diabetes

The National Institute for Health and Care Excellence (NICE) provides comprehensive, evidence-based guidance on the management of type 2 diabetes (NG28: Type 2 diabetes in adults: management). Current NICE guidelines focus on lifestyle interventions—including dietary modification, physical activity, and weight management—alongside pharmacological treatments such as metformin, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin. Cinnamon is not mentioned in NICE guidance as a recommended intervention for glycaemic control.

The NHS similarly emphasises evidence-based approaches to diabetes management. Whilst the NHS acknowledges patient interest in complementary therapies, it advises that such approaches should not replace conventional treatments. The NHS website states that people with diabetes should discuss any complementary therapies with their healthcare team to ensure safety and avoid interactions with prescribed medications.

NICE guidance on person-centred care encourages shared decision-making and respect for patient preferences, but this is within the context of treatments supported by robust evidence. Healthcare professionals are advised to provide clear information about the lack of evidence for unproven interventions and to support patients in making informed choices.

For patients interested in complementary approaches, the focus should remain on evidence-based lifestyle measures:

• Dietary modification: Following a balanced diet rich in vegetables, whole grains, and lean proteins, whilst limiting refined carbohydrates and saturated fats.

• Physical activity: The UK Chief Medical Officers' Physical Activity Guidelines (2019) recommend at least 150 minutes of moderate-intensity aerobic activity (or 75 minutes of vigorous-intensity activity) per week, plus muscle-strengthening activities on at least two days per week.

• Weight management: Achieving and maintaining a healthy weight can significantly improve insulin sensitivity and glycaemic control.

• Structured education: Programmes such as DESMOND (Diabetes Education and Self-Management for Ongoing and Newly Diagnosed) provide evidence-based support for self-management.

Patients should contact their GP or diabetes care team if they have concerns about blood glucose control, experience symptoms of hypo- or hyperglycaemia, or wish to discuss any aspect of their diabetes management, including complementary therapies. Regular monitoring, medication review, and structured education remain the cornerstone of effective type 2 diabetes care in the UK.

Frequently Asked Questions